Pharmaceutical Technology2h
Abcuro secures $200m as it eyes approval for rare muscle disease drug
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Pharmaceutical Technology3h
OCT West Coast 2025: China surpasses US for annual number of clinical trials
GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.
Pharmaceutical Technology5h
Lundbeck gains FDA fast track designation for MSA therapy amlenetug
Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...
Pharmaceutical Technology8h
FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
Pharmaceutical Technology9h
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment
EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.
Pharmaceutical Technology11h
Health Canada approves MSD’s Keytruda for NSCLC stages
Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...
Pharmaceutical Technology8h
Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
Pharmaceutical Technology23h
Be realistic, responsive and transparent: how to engage underperforming sites
Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that ...